Cure My Disease

Don't miss your cure!

 Log in / Sign up

New shot aims to tame rare autoimmune disease

NCT ID NCT07641634

Recruiting now Disease control Sponsor: Prolium Bioscience, Inc Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tests a new drug called PRO-203, given as a single shot under the skin. First, healthy volunteers will check safety; then, people with systemic sclerosis (a rare autoimmune disease that hardens skin and organs) will receive the drug. The main goal is to see if it's safe and how it affects immune cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
PRO-203 (a drug given as a shot under the skin)
What this could lead to
If it works, this could point toward a treatment that controls systemic sclerosis by targeting immune cells.
What could go wrong
This is a very early, small trial (44 people) focused on safety, not effectiveness. It may fail to show benefit or have side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEERS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

diffuse scleroderma scleroderma systemic sclerosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEERS SCLERODERMA SCLERODERMA, SYSTEMIC SYSTEMIC SCLEROSIS (SSC)

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Nanjing Drum Tower Hospital

    RECRUITING

    Nanjing, China

    Contact Email: •••••@•••••

  • Nucleus Network

    COMPLETED

    Melbourne, Victoria, 3004, Australia

  • Peking University Third Hospital

    RECRUITING

    Beijing, China

    Contact Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.